Printer Friendly

CLASS-ACTION SUIT PRESCRIBES RELIEF FOR MEDICAL CONSUMERS

 CLASS-ACTION SUIT PRESCRIBES RELIEF FOR MEDICAL CONSUMERS
 PHILADELPHIA, Jan. 8 /PRNewswire/ -- The recent settlement of a federal class-action suit against Bolar Pharmaceutical Company (AMEX: BLR) is a victory for consumer protection in the pharmaceutical industry, said lawyers involved in the case.
 On Nov. 11, federal judge Edward N. Cahn approved a settlement in the class-action suit against Bolar. Plaintiffs in the suit alleged that Bolar had falsified test results submitted to the U.S. Food and Drug Administration in support of Bolar's applications to sell generic formulations of the drugs Dyazide (triamterene/hydrochlorothiazide) and Macrodantin (nitrofurantoin macrocrystals). Under the terms of the settlement, Bolar admitted no wrongdoing, but agreed to establish a $3.8 million fund to settle the suit.
 Consumers who bought Bolar's generic versions of Dyazide or Macrodantin (drugs that treat high blood pressure and urinary tract infections, respectively) between Aug. 21, 1987, and Dec. 12, 1990, can file a claim.
 They can obtain a claim form by writing to Bolar Pharmaceutical Litigation, Department P, P.O. Box 57, Philadelphia, Pa., 19105, or by calling 800-222-2760. The completed claim form must be postmarked no later than Feb. 28, 1992.
 The case is one of a number of lawsuits brought by consumers in recent years. Such cases are significant because they help level the playing field between large companies and individual consumers, said Dianne M. Nast, a lawyer in the Philadelphia firm of Kohn, Klein, Nast & Graf, P.C. Nast is the lead attorney for the plaintiffs.
 A class-action suit, Nast explained, combines the individual small claims of many consumers. "If a company bilks a million customers of a dollar apiece, it has taken a million dollars. But it knows that nobody will sue over a single dollar. A class-action suit gives consumers a way to fight back," she said.
 Nast has prosecuted other significant class-action suits, including those in which Chrysler allegedly disconnected car odometers, Beechnut allegedly substituted sugared water for infant apple juice, Norelco marketed a water-purification system in which the filters allegedly contained carcinogens, and Hertz allegedly improperly charged customers for car repairs.
 Such suits are especially important in the pharmaceutical arena because consumers have little choice when it comes to buying prescription drugs. "Drug companies have been able to hold consumers hostage," Nast said. "If you get angry with Chrysler, you can buy a Ford. But when your health depends on a pill that your doctor prescribes, you generally can't boycott the drug. This case carries a clear message: Consumers can -- and will -- hold you accountable for your actions."
 /delval/
 -0- 1/8/92
 /CONTACT: Dianne M. Nast or Douglas A. Abrahams of Kohn, Klein, Nast & Graf, 215-238-1700/
 (BLR) CO: Bolar Pharaceutical Company; Kohn, Klein, Nast & Graf, P.C. ST: New York, Pennsylvania IN: MTC SU:


KA-MK -- PH011 -- 7728 01/08/92 11:10 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 1992
Words:470
Previous Article:PILLSBURY TO ACQUIRE FROZEN BUSINESS OF MCGLYNN BAKERIES
Next Article:AS HEALTHCARE COSTS APPROACH $1 TRILLION, SOME COMPANIES THRIVE, SAYS HAMBRECHT & QUIST
Topics:


Related Articles
COURT APPROVES $3.8 MILLION SETTLEMENT IN GENERIC DRUG CLASS ACTION SUIT
CLASS ACTION PETITION HEARING SET FOR SEPT. 16 IN DETROIT: TARGETS GENERIC PHARMACEUTICAL MAKER FOR PRODUCING FRAUDULENT, UNSAFE DRUGS
/ C O R R E C T I O N -- CLASS ACTION PETITION HEARING /
FEDERAL JUDGE GRANTS CLASS ACTION PETITION AGAINST GENERIC DRUG MAKER
Class Action Commenced Against Manufacturers of Diet Pills Marketed as Fen/Phen and Redux
Amended Complaint Seeking Class Action Status Filed Against Manufacturers of Diet Pills Marketed as Fen/Phen and Redux
Gilman and Pastor, LLP Files Class Action Suit Against Warner-Lambert Company and Parke-Davis Pharmaceuticals, Ltd. on Behalf of Purchasers and Users...
New Cox-2 pain relievers are marketing marvel, not miracle drugs.
Paxil class-action suit hits GSK.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters